Norynta Bio
For licensed business buyers · updated November 2026

Suppliers that pass today's rules, and the next ones

US tariffs on patented drugs, FDA import alerts, the BIOSECURE list, new Chinese export rules and a risky Gulf sea lane. We check suppliers against all of it before we introduce them. Free for buyers.

Request a verified quote

B2B only: licensed pharmacies, distributors, drug developers and manufacturers. No consumer sales, no health claims, no controlled substances. We never mis-declare goods or reroute them to avoid tariffs, sanctions or regulatory checks; every shipment declares its true origin and contents.

Questions

Are generic APIs subject to the US Section 232 pharmaceutical tariff?

Not at the moment. Since 2026 the US charges up to 100% on patented pharmaceuticals and their ingredients, while generics, biosimilars and their ingredients are excluded. The US Commerce Department must report within a year whether generics should be covered, so buyers should plan second sources now.

How do you check a supplier against FDA import alerts?

Before any introduction we check the manufacturing site, not just the trading company, against FDA import alerts (such as 66-40), recent warning letters and, for GLP-1 APIs, the FDA green list. Sites that fail are not introduced.

What is the BIOSECURE Act list and when is it due?

BIOSECURE (US NDAA FY2026, section 851) restricts federal contracts and grants that use equipment or services from designated biotechnology companies of concern. The first list is due by December 18, 2026. We offer verified alternatives for buyers who need to stay eligible.

Can you deliver temperature-controlled goods to the UAE while the Strait of Hormuz is risky?

Yes, through licensed GDP cold-chain partners, by air or via east-coast UAE and Oman ports with bonded trucking, with the importer's MOHAP/EDE permits in place.

What does it cost?

Nothing for buyers. Suppliers pay a published success fee after you have paid them; it is never added to your price.

Request a verified quote

General information, not legal or regulatory advice. Sources: Section 232 pharmaceutical proclamation (April 2026) and CBP guidance; FDA import alerts and warning letters; NDAA FY2026 section 851; MOFCOM/MOST Announcement No. 48 (October 2026).